Boehringer Ingelheim has signed a €500m ($572m) agreement with UK-based biotech Tessellate Bio to co-develop targeted cancer ...

Biotech firms are engineering smarter, safer gene delivery systems to enhance the safety and efficacy of genetic medicines.

Certain DNA sequences can form structures other than the canonical double helix. These alternative DNA conformations—referred ...

The €500 million deal is Tessellate's first with a pharmaceutical company and focuses on advancing synthetic lethality therapies.

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

For uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone plus azithromycin, according to a study published online April 14 in The ...

An INRS research team has identified a new family of enzymes that can make precise cuts in single-stranded DNA. A few years ago, the introduction of CRISPR technology marked a significant breakthrough ...

Researchers have uncovered the 3D structure of RBP3, a key protein in vision, revealing how it transports retinoids and fatty ...

A new study from Weill Cornell Medicine provides insights into how cells maintain the tiny end caps of chromosomes as they ...

Gepotidacin is a new oral antibacterial treatment with the potential to become an alternative option for treating infections.

For the first time, Professor Veyrier and his team at INRS have discovered a family of enzymes that can cut specific sequences in single-stranded DNA. These enzymes, called site-specific ...

Recently, Professor Frédéric Veyrier at the Institut national de la recherche scientifique (INRS) and his team developed a new genetic tool based on a family of specific enzymes called Ssn that allows ...